Tempus AI’s TEM stock has surged nearly 13% since its second-quarter 2025 earnings release. The quarter saw strong top-line ...

Tempus AI achieves strong revenue growth and beats expectations, but ongoing losses and execution risks temper enthusiasm.

In conjunction with its better-than-expected sales growth in the second quarter, Tempus AI raised its sales outlook for this ...

Tempus AI, Inc. (NASDAQ:TEM) investors will be delighted, with the company turning in some strong numbers with its latest results. Results overall were solid, with revenues arriving 5.7% better than ...

Tempus AI TEM stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, rising from 66 to 78. Please ...

After Tempus AI’s Q2 earnings release, analysts at Morgan Stanley increased their price target on the stock from $65 to $68.

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...

Tempus AI shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 82.

Bioventus Inc. (NASDAQ:BVS) is one of the best medical device stocks to buy according to analysts. On August 7, Craig-Hallum ...

In a report released on August 8, Subbu Nambi from Guggenheim reiterated a Buy rating on Tempus AI, Inc. Class A, with a price target of $75.00. The company’s shares closed last Friday at $60.87.

Dan Ives' AI Revolution ETF (IVES) is heavily weighted toward big tech, betting these giants will lead the AI boom. Click ...

Ballie Gifford is one of the best growth investors in the world and has been almost form inception. The firm was founded in ...